Treatment of experimental non-alcoholic steatohepatitis by targeting α7 nicotinic acetylcholine receptor-mediated inflammatory responses in mice

Molecular Medicine Reports

Volumn 12, Issue 5, 2015, Pages 6925-6931

  Zhou, Zhou ^a   Liu, Ying Chao ^a   Chen, Xiao Mei ^a   Li, Fu Qiang ^a   Tong, Xiao Juan ^a   Ding, Yue Ping ^a   Tang, Cui Lan ^a  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

Inflammation; Interleukin 6; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Nuclear factor kappa B; Tumor necrosis factor ; 7 nicotinic acetylcholine receptor

Indexed keywords

BUNGAROTOXIN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; NICOTINIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG TARGETING; IN VITRO STUDY; IN VIVO STUDY; KUPFFER CELL; LIPID DIET; LIPID LIVER LEVEL; LIVER CELL; LIVER INJURY; LIVER NECROSIS; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; UPREGULATION; WESTERN BLOTTING; ADVERSE EFFECTS; AGONISTS; ANIMAL; CELL LINE; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; DIET, HIGH-FAT; INFLAMMATION; INTERLEUKIN-6; LIVER; MALE; MICE; NF-KAPPA B; NICOTINE; NICOTINIC AGONISTS; NON-ALCOHOLIC FATTY LIVER DISEASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84943602280     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4318     Document Type: Article

References (32)

1. Noureddin M, Yates KP, Vaughn IA, Neuschwander-Tetri BA, Sanyal AJ, McCullough A, Merriman R, Hameed B, Doo E, Kleiner DE, et al: Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 58: 1644-1654, 2013.
2. Evans CD, Oien KA, MacSween RN and Mills PR: Non-alcoholic steatohepatitis: A common cause of progressive chronic liver injury?. J Clin Pathol 55: 689-692, 2002.
3. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF and Zein NN: The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51: 1972-1978, 2010.
4. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A and Angulo P: The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 129: 113-121, 2005.
5. Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM and Schwimmer JB: Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. AM J Gastroenterol 103: 2263-2271, 2008.
6. Wong VW, Wong GL, Tsang SW, Fan T, Chu WC, Woo J, Chan AW, Choi PC, Chim AM, Lau JY, et al: High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut 60: 829-836, 2011.
7. Gastaldelli A, Kozakova M, Højlund K, Flyvbjerg A, Favuzzi A, Mitrakou A and Balkau B: Fatty liver is associated with insulin resistance, risk of coronary heart disease and early atherosclerosis in a large European population. Hepatology 49: 1537-1544, 2009.
8. Bilici A, Ozguroglu M, Mihmanli I, Turna H and Adaletli I: A case-control study of non-alcoholic fatty liver disease in breast cancer. Med Oncol 24: 367-371, 2007.
9. Pagadala MR, Zein CO, Dasarathy S, Yerian LM, Lopez R and McCullough AJ: Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci 57: 528-534, 2012.
10. Caballería L, Auladell MA, Torán P, Miranda D, Aznar J, Pera G, Gil D, Muñoz L, Planas J, Canut S, et al: Prevalence and factors associated with the presence of non alcoholic fatty liver disease in an apparently healthy adult population in primary care units. BMC Gastroenterol 7: 41, 2007.
11. Gelpi Méndez JA, Castellanos Fillot A, Sainz Gutiérrez JC, Quevedo Aguado L and Martin Barallat J: Prevalence of non-alcoholic fatty liver disease and associated risk factors among managers from the community of Madrid. Arch Prev Riesgos Labor 17: 84-90, 2014 (In Spanish).
12. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA and Cardoso CR: Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 29: 113-119, 2009.
13. Loria P, Lonardo A, Lombardini S, Carulli L, Verrone A, Ganazzi D, Rudilosso A, D'Amico R, Bertolotti M and Carulli N: Gallstone disease in non-alcoholic fatty liver: Prevalence and associated factors. J Gastroen Hepatol 20: 1176-1184, 2005.
14. Radu C, Grigorescu M, Crisan D, Lupsor M, Constantin D and Dina L: Prevalence and associated risk factors of non-alcoholic fatty liver disease in hospitalized patients. J Gastrointestin Liver Dis 17: 255-260, 2008.
15. Hu KC, Wang HY, Liu SC, Liu CC, Hung CL, Bair MJ, Liu CJ, Wu MS and Shih SC: Nonalcoholic fatty liver disease: Updates in noninvasive diagnosis and correlation with cardiovascular disease. World J Gastroenterol 20: 7718-7729, 2014.
16. Sanyal AJ: NASH: A global health problem. Hepatol Res 41: 670-674, 2011.
17. Takaki A, Kawai D and Yamamoto K: Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). Int J Mol Sci 15: 7352-7379, 2014.
18. Musso G, Anty R and Petta S: Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients? Curr Pharm Des 19: 5297-5313, 2013.
19. Yalcin M, Akarsu M, Celik A, Sagol O, Tunali S, Ertener O, Bengi G and Akpinar H: A comparison of the effects of infliximab, adalimumab, and pentoxifylline on rats with non-alcoholic steatohepatitis. Turk J Gastroenterol. 25: 167-175, 2014.
20. Fock KM and Khoo J: Diet and exercise in management of obesity and overweight. J Gastroenterol Hepatol 28: 59-63, 2013.
21. Beaton MD: Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Can J Gastroenterol 26: 353-357, 2012.
22. Malaguarnera M, Di Rosa M, Nicoletti F and Malaguarnera L: Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl) 87: 679-695, 2009.
23. Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC and Sarin SK: Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical and metabolic parameters of patients with nonalcoholic steatohepatitis. AM J Gastroenterol 99: 1946-1952, 2004.
24. Mitchel EB and Lavine JE: Review article: The management of paediatric nonalcoholic fatty liver disease. Aliment Pharmacol Ther 40: 1155-1170, 2014.
25. Filippini P, Cesario A, Fini M, Locatelli F and Rutella S: The Yin and Yang of non-neuronal α7-nicotinic receptors in inflammation and autoimmunity. Curr drug targets 13: 644-655, 2012.
26. Boeckxstaens G: The clinical importance of the anti-inflammatory vagovagal reflex. Handb Clin Neurol 117: 119-134, 2013.
27. Ganz M and Szabo G: Immune and inflammatory pathways in NASH. Hepatol int 7: 771-781, 2013.
28. Meli R, Mattace Raso G and Calignano A: Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol 5: 177, 2014.
29. Braunersreuther V, Viviani GL, Mach F and Montecucco F: Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol 18: 727-735, 2012.
30. Weiß J, Rau M and Geier A: Non-alcoholic fatty liver disease epidemiology, clinical course, investigation, and treatment. Dtsch Arztebl Int 111: 447-452, 2014.
31. Ratziu V, Goodman Z and Sanyal A: Current efforts and trends in the treatment of NASH. J Hepatol 62: S65-S75, 2015.
32. Gadd VL, Skoien R, Powell EE, Fagan KJ, Winterford C, Horsfall L, Irvine K and Clouston AD: The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver. Hepatology 59: 1393-1405, 2014.